Shots:
- ALPCO has launched its Calprotectin Immunoturbidimetric Assay for the diagnosis of IBD, incl. Crohn’s disease & ulcerative colitis in the EU
- ALPCO has also enrolled 1st pts in its pivotal trial for FDA clearance of its automated chemiluminescent calprotectin assay on the KleeYa system, following completion of the FDA pre-submission in Mar 2025, with enrolment beginning in Apr 2025
- Calprotectin assay aids in in vitro diagnosis of IBD while differentiating it from IBS when used with other clinical data, offering 90.5% sensitivity & 93.4% specificity. Addition of the chemiluminescent platform will enhance automation, providing a simplified & scalable solution for calprotectin testing
Ref: PRNewswire | Image: ALPCO
Related News:- J&J MedTech Reports First Patient Enrollment in FORWARD CAD trial of Shockwave Javelin Coronary IVL Catheter
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click Here for Full Press Release
